NewEdge Advisors’s Pacira BioSciences PCRX Stock Holding History

NewEdge Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.54K	Hold	100	–	–	﹤0.01%	3874
2026 Q1	$2.26K	Hold	100	–	–	﹤0.01%	3785
2025 Q4	$2.59K	Hold	100	–	–	﹤0.01%	3836
2025 Q3	$2.58K	Hold	100	–	–	﹤0.01%	3726
2025 Q2	$2.39K	Hold	100	–	–	﹤0.01%	3581
2025 Q1	$2.48K	Hold	100	–	–	﹤0.01%	3462
2024 Q4	$1.88K	Hold	100	–	–	﹤0.01%	3461
2024 Q3	$1.5K	Hold	100	–	–	﹤0.01%	3441
2024 Q2	$2.86K	Hold	100	–	–	﹤0.01%	3264
2024 Q1	$2.92K	Sell	100 -187	-65%	-$5.75K	﹤0.01%	3292
2023 Q4	$9.68K	Hold	287	–	–	﹤0.01%	2862
2023 Q3	$8.8K	Hold	287	–	–	﹤0.01%	2617
2023 Q2	$11.5K	Buy	287 +187	+187%	+$7.73K	﹤0.01%	2556
2023 Q1	$4.08K	Sell	100 -4	-4%	-$159	﹤0.01%	2847
2022 Q4	$4	Buy	+104	New	+$5.06K	﹤0.01%	3854
2017 Q3	–	Sell	-158	Closed	-$7.8K	–	891
2017 Q2	$7.8K	Buy	+158	New	+$7.33K	﹤0.01%	1042

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

NewEdge Advisors's PCRX Position: Q2 2026 in Review

NewEdge Advisors held its Pacira BioSciences (PCRX) position steady in Q2 2026 at 100 shares worth $2.54K. The position accounts for ﹤0.01% of the portfolio, ranked #3874.

NewEdge Advisors first reported a position in PCRX in Q2 2017 and has held it in 16 quarters since. The position peaked at $11.5K in Q2 2023. 183 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

NewEdge Advisors held 100 shares of Pacira BioSciences worth $2.54K as of Q2 2026.
NewEdge Advisors left its Pacira BioSciences share count unchanged in Q2 2026.
Pacira BioSciences made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3874 holding.
NewEdge Advisors first reported a position in Pacira BioSciences in Q2 2017 and has held it in 16 quarters since.
NewEdge Advisors's Pacira BioSciences position peaked at $11.5K in Q2 2023.
183 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.